Novo Nordisk unveiled its latest data for a weight-loss drug candidate, but shares of the maker of Wegovy and Ozempic tumbled ...

Novo Nordisk said on Monday it would halt its collaboration with U.S. telehealth company Hims & Hers Health over the ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

Novo Nordisk announced it will stop collaborating with Hims & Hers Health regarding the distribution of Wegovy weight loss ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...